Inclusion Criteria:  Patients diagnosed with Functional Dyspepsia using Rome IV diagnostic criteria: patients on prior dyspepsia treatment can be recruited after washout period of 2 weeks Subject who has ability to provide written informed consent and willingness to comply with the requirement of the protocol Able to communicate in English, Malay or Mandarin languages  Exclusion Criteria:  Patients with known hypersensitivity to Itopride and/or proton pump inhibitors or to any of the excipients of the study medication Patients with a contraindication to any of the study drugs Pregnant / breast feeding women Presence of family history of GI malignancy or alarm features suggested malignancy - e.g. Unintentional weight loss (≥ 10% of body weight in recent 6 months), GI bleeding Patients consuming regular Aspirin or NSAIDs (except low-dose Aspirin at a dose of 325 mg/day or less for cardiovascular prophylaxis) History of erosive esophagitis, peptic ulcer disease within 1 year prior to the screening History of gastrointestinal (GI) malignancy, primary esophageal motility disorder, documented upper GI surgery Patients with any hepatobiliary or pancreatic diseases Patients with severe depression, anxiety, or other psychological disorder Patients with any terminal disease Presence of irritable bowel syndrome (Rome IV criteria) or inflammatory bowel disease (IBD) Other conditions determined by the investigator to be inappropriate for this clinical study